Merck KGaA Plumps For Reinvention To Refuel R&D
Aim Is To Launch A New Product Every 1.5 Years
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
You may also be interested in...
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.